Blue Food Innovation Summit: Nutrition, genetics will be key aquaculture focus for next five years
Undercurrent News is reporting live from this year's Blue Food Innovation Summit in London, UK from June 14-15
UK single-cell protein maker gets £4.8m in funds from gov’t
The funding will be used to finance the 'Deep Blue C' project, accelerating Deep Branch's growth as it commercializes its CO2-to-protein technology platform
New Israeli startup to focus on cell-cultivated tilapia
Israeli investment company BioMeat Foodtech has announced the founding of E-FISHient Protein, a joint startup with Israel's Volcani Institute
Inaugural ‘Blue Food Innovation Summit’ approaches
The event will feature 23 innovators from across the globe with breakthrough technologies in aquaculture and blue food, seeking opportunities to scale through partnerships and investment
China’s Dao Foods invests in plant-based seafood startup, five others
This cohort of firms included Singapore-based Lohas Foods, a maker of 'hyper-realistic plant-based seafood'
UK caviar firm readies for world’s first cell-cultivated sturgeon roe by 2023
Exmoor Caviar hopes to have cell-cultivated sturgeon caviar marketed in Japan by late 2023 and in Europe and the US in 2025
CULT to invest in US cell-based oyster culture startup
Oysters used to be abundant around the world, but more than 85% of wild oyster reefs have been lost globally
Hatch launches €50m investment plan for ‘regenerative’ aquaculture
The group boasts venture partners including Kingfish Zeeland chair Hans den Biemen and Delta Blue CEO Jeff Fort, plus advisors like Einar Wathne, Darian McBain, and Magdalena Wallhoff Lamprecht
‘Alternative’ seafood investments hit $175m in 2021 as cell-cultivated interest grew
Investment in plant-based, cell-cultivated and fermented seafood alternatives has reached $313m since 2013
Galletti: Seafood firms need to embrace plant, cell-based protein products
Sam Galletti, president of US importer and processor Southwind Foods, sees only downsides from the seafood sector ignoring the demand for plant and cell-based alternatives